| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V56074 | (1R,2S)-NCD38 TFA | 2078047-42-2 | (1R,2S)-NCD38 TFA is an enantiomer of NCD38 TFA. |
|
V0372 | IOX1 | 5852-78-8 | IOX1 (5-Carboxy-8-hydroxyquinoline) is a novel, potent and broad-spectrum inhibitor of 2OG oxygenases (e. |
|
V94227 | Acaricide | The acaricide (compound 7l) is a potent LSD1 inhibitor. | |
|
V128069 | Acaricide agent 1 | Acaricide agent 1 is a potent LSD1 inhibitor. | |
|
V2982 | AS8351 | 796-42-9 | AS8351 is a potent inhibitor of KDM5B (lysine-specific histone demethylase 5B) which plays an important role in maintaining cancer stem cells and justifies the rationale for studying the effects of continuous inhibition of this epigenetic factor in cancer. |
|
V56067 | CBB1007 hydrochloride | 2070014-96-7 | CBB1007 HCl is a highly efficient substrate competitive, reversible, and selective inhibitor of the histone demethylase LSD1, with IC50 of 5.27 uM for hLSD1. |
|
V2606 | CPI-455 | 1628208-23-0 | CPI-455 is a novel, potent andspecific inhibitor of the KDM5demethylase which catalyzes the demethylation of histone H3 on lysine 4 (H3K4) and is required for the survival of drug-tolerant persister cancer cells (DTPs). |
|
V2936 | DDP-38003 dihydrochloride | 1831167-98-6 | DDP-38003 dihydrochloride, atranylcypromine (TCPA) derivative, is a novel, potent and orally bioavailable inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1). |
|
V77096 | DDP-38003 trihydrochloride | DDP-38003 triHCl is a novel, orally bioactive KDM1A/LSD1 inhibitor (antagonist) with IC50 of 84 nM. | |
|
V52030 | GSK 690 Hydrochloride | 2436760-79-9 | GSK 690 ( HCl) is a reversible inhibitor of lysine-specific demethylase 1 (LSD1) with a Kd of 9 nM and IC50 of 37 nM. |
|
V4761 | GSK J4 HCl | 1797983-09-5 | GSK J4 (GSK-J4) is a novel,cell permeable, and potent prodrug of GSK J1 with anti-inflammatory effects. |
|
V45816 | GSK-690 HCl | GSK-690 hydrochloride is a selective reversible inhibitor of lysine specific demethylase 1(LSD1) with anticancer activity. | |
|
V2660 | GSK-J4 | 1373423-53-0 | GSK J4 is a novel,cell permeable, and potent prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase (KDM) JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and is inactive against a panel of demethylases of the JMJ family. |
|
V52029 | GSK-LSD1 dihydrochloride | 2102933-95-7 | GSK-LSD1 diHCl is a potent, selective, irreversible inhibitor of lysine-specific demethylase (LSD1) with IC50 of 16 nM. |
|
V4128 | GSK2807 TFA | 2245255-66-5 | GSK2807 TFA (GSK-2807 TFA), the trifluoroacetic acid salt form ofGSK2807, is a selective and SAM-competitiveSMYD3inhibitorwith potential antitumor activity. |
|
V0371 | JIB-04 (NSC-693627) | 199596-05-9 | JIB-04 (also known as NSC693627) is anovel, potent and pan-selective inhibitor of Jumonji histone demethylase (JMJD) inhibitor with antineoplastic activity. |
|
V51918 | JNJ-9350 | 326923-09-5 | JNJ-9350 is an inhibitor (blocker/antagonist) of spermine oxidase (SMOX) with IC50 of 0.01 μM. |
|
V80481 | KDOAM-25 trihydrochloride | KDOAM-25 tri HCl is a potent and selective inhibitor of histone lysine demethylase 5 (KDM5), with IC50s of 71 nM, 19 nM, 69 nM, and 69 nM for KDM5A, KDM5B, KDM5C, and KDM5D respectively. | |
|
V85462 | LSD1-IN-30 | 1289575-45-6 | |
|
V139086 | LSD1-IN-43 | LSD1-IN-43 is a highly selective, reversible, orally effective LSD1 inhibitor that can cross the blood-brain barrier, with an IC50 value of 0.8 μM. |